Clinical Trials Browser

Interventional × veliparib × Clear all

NCT00740805 2026-03-18

Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma

Phase 1 Active not recruiting

Ann Arbor Stage III Non-Hodgkin Lymphoma

NCT01351909 2026-03-18

Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT01386385 2026-03-18

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 1/2 Active not recruiting

53 enrolled 21 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT01434316 2026-03-18

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT02152982 2026-03-18

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2/3 Active not recruiting

447 enrolled 20 charts

Glioblastoma, Gliosarcoma

NCT03289910 2026-03-18

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Phase 2 Active not recruiting

25 enrolled 15 charts

MyeloidOther hematologic neoplasm

Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT02890355 2026-03-05

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

123 enrolled 15 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02158507 2026-01-22

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Phase NA Completed

20 enrolled 10 charts

Triple Negative Breast Neoplasms

NCT02921256 2025-12-04

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

Phase 2 Completed

363 enrolled 16 charts

Gastrointestinal

Rectal Neoplasms

NCT01251874 2025-11-21

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01139970 2025-11-20

Veliparib and Temozolomide in Treating Patients With Acute Leukemia

Phase 1 Completed

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01638546 2025-10-29

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase 2 Active not recruiting

97 enrolled 12 charts

Small Cell Lung Carcinoma

NCT01012817 2025-09-15

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Phase 1/2 Active not recruiting

88 enrolled 23 charts

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT01149083 2025-08-15

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Phase 2 Completed

77 enrolled 17 charts

Breast Neoplasms

NCT02595905 2025-05-16

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Phase 2 Completed

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01818063 2025-04-30

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

Phase 2 Completed

9 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00576654 2025-04-15

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 1 Completed

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01009788 2025-03-14

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

Phase 2 Completed

63 enrolled 11 charts

Breast Neoplasms

NCT01585805 2025-03-11

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT02163694 2025-02-19

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Phase 3 Completed

513 enrolled 16 charts

Breast Neoplasms

NCT01205828 2025-02-12

ABT-888 and Temozolomide for Liver Cancer

Phase 2 Terminated

16 enrolled 11 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02631733 2025-02-10

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Phase 1 Completed

Other solid neoplasm

Malignant Solid Neoplasm

NCT02470585 2024-10-26

VELIA

Phase 3 Terminated

1,140 enrolled 29 charts

Ovarian Neoplasms

NCT01618357 2024-05-22

Pre-Operative Radiation and Veliparib for Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT03044795 2024-05-03

REPAIR

Phase 2 Withdrawn

Neoplasms

NCT01827384 2023-09-29

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Phase 2 Completed

208 enrolled 27 charts

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT01642251 2023-05-06

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase 1/2 Completed

156 enrolled 13 charts

EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Neuroendocrine, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT02723864 2022-02-08

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

Phase 1 Completed

53 enrolled 20 charts

Neoplasms

NCT03400306 2021-12-08

A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Phase 1 Withdrawn

Ovarian Neoplasms

NCT01063816 2021-08-02

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT01123876 2021-08-02

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Phase 1 Completed

Gastrointestinal

Stomach Neoplasms

NCT02860819 2021-03-03

Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer

Phase 2 Completed

Testicular Neoplasms

NCT02264990 2021-02-26

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Phase 3 Completed

595 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03227016 2021-01-27

Study in Patients With SCLC of Veliparib in Combination With Topotecan

Phase 1 Unknown

Small Cell Lung Carcinoma

NCT02032277 2021-01-20

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Phase 3 Completed

Neoplasms, Triple Negative Breast Neoplasms

NCT02106546 2020-11-17

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01576172 2020-11-12

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

159 enrolled 12 charts

Prostatic Neoplasms

NCT01908478 2020-07-15

VelGemRad

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT01749397 2020-07-02

Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Phase 1 Completed

Stage IV Fallopian Tube Cancer AJCC v6 and v7

NCT02289690 2020-05-14

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

Phase 1/2 Completed

221 enrolled 37 charts

Small Cell Lung Carcinoma

NCT01445522 2019-12-17

ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer

Phase 1 Completed

Lymphoma, Neoplasms

NCT00994071 2019-12-09

A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors

Phase 1 Completed

Astrocytoma, Brain Neoplasms, Ependymoma, Medulloblastoma, Neuroectodermal Tumors, Primitive

NCT02944396 2019-10-23

Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01266447 2019-08-08

Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

Phase 2 Completed

27 enrolled 11 charts

Uterine Cervical Neoplasms

NCT01540565 2019-07-23

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

52 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01459380 2019-07-22

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 1 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01281852 2019-07-18

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Phase 1 Completed

Uterine Cervical Neoplasms

NCT01051596 2019-04-02

A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer

Phase 2 Completed

75 enrolled 10 charts

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT02305758 2018-11-20

Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer

Phase 2 Completed

130 enrolled 12 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms